Kouki Harasaki, Ph.D. is the Founding / Managing Partner at Bioluminescence Ventures. He has over 20 years of biomedical science experience working across major health systems, research institutes, biopharmaceutical corporations, technology companies, and venture capital firms. Prior to founding Bioluminescence Ventures, he was Managing Director at M12 / Microsoft Ventures, where he led Life Sciences investments and helped develop Microsoft corporate strategy in the field. Before M12, Dr. Harasaki was a senior Partner at Andreessen Horowitz (Bio Fund).

Prior to his time in venture, Dr. Harasaki held Drug Discovery, Animal Pharmacology, Strategy, Finance, and Business Development roles at Novartis AG and Baxalta/Shire. He has led over $600M in financing deals that have funded more than 25 therapeutics programs across stages (discovery to marketed), across therapeutic areas (CVM, Immunology, Oncology, Neuro/CNS), and across modalities (small molecules, biologics, genome editors, cell therapies).

Campbell Murray, M.D. joined Bioluminescence Ventures as a Senior Partner in 2024, bringing over two decades of experience in venture capital, biotech operations, and clinical medicine. Prior to BLV, Dr. Murray was a general partner at Agent Capital. Previously, he spent more than 16 years with Novartis Venture Fund (NVF), where as Managing Director he invested over $200 million across a portfolio that yielded 6 M&A exits and 11 IPOs. His entrepreneurial experience includes serving as President & Chief Operating Officer of Diabetes Free and Intima Bioscience, and he has served on the Board of Directors of 22 emerging biotechnology companies.

Chloe Kim, Ph.D. joined Bioluminescence Ventures as a Partner in 2022. Dr. Kim is a biomedical engineer / cell biologist by training with scientific expertise across regenerative medicine, oncology, immunology, and neuroscience. Prior to joining BLV, she worked in business development and corporate strategy at a major Korean biopharmaceutical company. Prior to that, she worked as a life science strategy consultant at Charles River Associates in San Francisco, where she specialized in commercial strategy projects for oncology and immunology therapeutics.

Negin Mokhtari, Ph.D., joined Bioluminescence Ventures as a Partner in 2023, bringing a blend of scientific expertise, operational experience, and investment acumen to her role. Her career has spanned a diverse range of roles, including academic scientist, founding team member of startups focused on drug delivery and high-throughput drug screening, and managing late-stage commercial operations at Freenome. Before joining BLV, Negin was part of the investment team at Genoa Ventures, where she focused on early-stage biotechnology investments and served on the boards of multiple companies.

Negin aims to integrate her scientific background, operational, and investment experience to support transformative advancements in life sciences and positively impact the lives of patients.

Andy Seid joined Bioluminescence Ventures as a Partner in 2023, bringing extensive experience spanning investment banking and operational expertise within the biopharmaceutical sector. With over 18 years in driving enterprise value creation, Mr. Seid has a proven track record of achieving successful business and financial outcomes. Prior to BLV, he served as director in the global healthcare investment banking group at Bank of America where he partnered with CEOs, CFOs and board members in identifying and executing financial and strategic outcomes through fundraising (IPOs, follow-ons, private placements) and M&A transactions. He held similar roles at Leerink Partners and UBS and collectively has led over 50 completed transactions in the life sciences space. As a biopharma operator, he has driven successful corporate, business development and strategic finance outcomes across small and large biopharmaceutical companies including Genentech and Sangamo.

Shailaja Uttamsingh, Ph.D. joined Bioluminescence Ventures as Partner in 2023, bringing two decades of experience in global development and lifecycle management of oncology therapies. She has contributed scientific and clinical expertise to all stages of drug development, including preclinical and translational research, regulatory strategy, clinical development plans and commercial strategy. Prior to joining BLV, she served as head of clinical science at Exelixis where she led and advanced several clinical programs in the growing portfolio and played a key role in business development strategy and external collaborations. Previously, she held roles in clinical development, medical affairs and clinical operations at Celgene (acquired by BMS), Oncomed, Genentech and Amgen, working on antibodies, ADCs, cell therapies, immune checkpoint inhibitors and targeted therapies.

Geney Park joined Bioluminescence Ventures in 2024 as an Operating Partner, bringing hands on experience from previous roles at Ossium Health where she served as the Senior Executive Assistant to the CEO, Co-Founder & President and managed events and marketing initiatives for the world’s first on-demand bone marrow bank. Earlier in her career, Geney served in various marketing and communications roles across health, wellness, fitness and technology training organizations.